Summary & Overview
HCPCS Level II J3055: Injection, talquetamab-tgvs, 0.25 mg
HCPCS Level II code J3055 denotes the injectable monoclonal antibody talquetamab-tgvs at a unit dose of 0.25 mg. As a product-specific HCPCS Level II code, J3055 is used on medical claims to identify administration of this targeted therapy in outpatient infusion settings and hospital outpatient departments. Nationally, accurate coding of J3055 matters for clinical documentation, claims processing, utilization tracking, and payer coverage determinations for novel oncology biologics.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J3055 represents, typical sites of service, and the clinical context of a monoclonal antibody injection. The publication also summarizes common billing modifiers associated with infusion and drug administration, payer coverage considerations, and operational benchmarks where available.
This briefing is intended to inform coding professionals, revenue cycle staff, and policy analysts about the role of HCPCS Level II code J3055 in billing workflows, payer interactions, and administrative reporting for a newly assigned biologic therapy.
Billing Code Overview
HCPCS Level II code J3055 represents injection, talquetamab-tgvs, 0.25 mg. This code identifies administration of the specified monoclonal antibody therapy in a parenteral injectable form.
-
Service type: Therapeutic injection (monoclonal antibody)
-
Typical site of service: Outpatient clinic or hospital outpatient infusion center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsed or refractory multiple myeloma who qualifies for treatment with talquetamab-tgvs, a bispecific monoclonal antibody targeting GPRC5D and CD3. The patient presents to an outpatient oncology infusion center for administration of J3055 (injection, talquetamab-tgvs, 0.25 mg) as part of a prescribed dosing regimen after prior evaluation by the treating hematologist/oncologist. Prior to dosing, the clinical workflow includes verification of the order, weight and vital signs assessment, review of recent laboratory results (complete blood count, hepatic and renal panels), assessment for active infections, and documentation of prior therapies and response. Infusion center nursing performs drug preparation per manufacturer guidance, checks for patient-specific contraindications (including pregnancy status), and establishes IV access or performs subcutaneous injection as indicated by the product specification.
During administration, nursing monitors for infusion- or injection-related reactions and cytokine release syndrome, documents medications given for prophylaxis or treatment (e.g., antipyretics, antihistamines, corticosteroids), and records start and stop times and lot number/expiration of the biologic. The prescribing hematologist/oncologist evaluates the patient post-administration for adverse events and adjusts future dosing or supportive care as indicated. Billing for the administered drug uses J3055 per 0.25 mg increment, with appropriate modifier reporting for site of service, patient status, and drug disposition when required.
Coding Specifications
| Modifier | Description | When to Use |
|---|